- Home
- APVO vs VLCN Comparison
APVO vs VLCN Comparison
Compare APVO & VLCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- VLCN
- Stock Information
- Founded
- APVO 2016
- VLCN 2020
- Country
- APVO United States
- VLCN United States
- Employees
- APVO N/A
- VLCN N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- VLCN Auto Manufacturing
- Sector
- APVO Health Care
- VLCN Consumer Discretionary
- Exchange
- APVO Nasdaq
- VLCN Nasdaq
- Market Cap
- APVO 3.3M
- VLCN 3.0M
- IPO Year
- APVO N/A
- VLCN 2021
- Fundamental
- Price
- APVO $0.67
- VLCN $0.84
- Analyst Decision
- APVO Strong Buy
- VLCN
- Analyst Count
- APVO 1
- VLCN 0
- Target Price
- APVO $296.00
- VLCN N/A
- AVG Volume (30 Days)
- APVO 8.7M
- VLCN 83.6K
- Earning Date
- APVO 05-07-2025
- VLCN 05-06-2025
- Dividend Yield
- APVO N/A
- VLCN N/A
- EPS Growth
- APVO N/A
- VLCN N/A
- EPS
- APVO N/A
- VLCN N/A
- Revenue
- APVO N/A
- VLCN $4,037,191.00
- Revenue This Year
- APVO N/A
- VLCN N/A
- Revenue Next Year
- APVO N/A
- VLCN N/A
- P/E Ratio
- APVO N/A
- VLCN N/A
- Revenue Growth
- APVO N/A
- VLCN 23.80
- 52 Week Low
- APVO $0.60
- VLCN $0.66
- 52 Week High
- APVO $51.06
- VLCN $330.40
- Technical
- Relative Strength Index (RSI)
- APVO 30.74
- VLCN 45.61
- Support Level
- APVO $0.60
- VLCN $0.75
- Resistance Level
- APVO $0.80
- VLCN $0.85
- Average True Range (ATR)
- APVO 0.19
- VLCN 0.07
- MACD
- APVO 0.03
- VLCN 0.02
- Stochastic Oscillator
- APVO 6.97
- VLCN 79.49
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.